Novartis Q3 2025 Financial Results

Novartis reported solid financial performance for Q3 2025, with net sales increasing by 7% in constant currencies to USD 13.9 billion. Core operating income grew by 7% to USD 5.5 billion, driven by strong performance from key products such as Kisqali, Kesimpta, Pluvicto, and Scemblix. The company reaffirmed its full-year 2025 guidance, expecting high single-digit sales growth and low-teens core operating income growth. Key milestones included FDA approval for Rhapsido in chronic spontaneous urticaria and positive Phase III readouts for ianalumab in Sjögren’s disease. Novartis also highlighted its strategic focus on accelerating growth, delivering returns, and strengthening foundations in its core therapeutic areas.